

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings of claims in the application:

**Listing of Claims:**

1. (original) A crystal of a protein-ligand complex comprising a protein-ligand complex of an N-terminal truncated factor VIII and a ligand, wherein the crystal effectively diffracts X-rays for the determination of the atomic coordinates of the protein-ligand complex to a resolution of greater than 5.0 Angstroms; and wherein the N-terminal truncated factor VIII:

(a) lacks at least 2000 amino acids from the flexible N-terminus of the corresponding full-length factor VIII; and

(b) retains the C2 domain of the corresponding full-length factor VIII.

2. (original) The crystal of claim 1, wherein the ligand comprises a phospholipid.

3. (canceled)

4. (original) The crystal of claim 1, wherein the ligand is glycerophosphorylserine.

5. (original) The crystal of claim 1, having space group of  $P2_12_12_1$  and a unit cell of dimensions of  $a=46$ ,  $b=57$ , and  $c=66$  Angstroms.

6. (original) The crystal of claim 1, wherein the N-terminal truncated factor VIII has secondary structural elements that include an eight-stranded, antiparallel  $\beta$ -barrel arranged in the order:  $\beta$ -sheet (1),  $\beta$ -sheet (2),  $\beta$ -sheet (3),  $\beta$ -sheet (4),  $\beta$ -sheet (5),  $\beta$ -sheet (6),  $\beta$ -sheet (7),  $\beta$ -sheet (8).

7. (canceled)

8. (canceled)

9. (canceled)

10. (canceled)

11. (original) A method of using the crystal of claim 1 in a drug screening assay, comprising:

(a) selecting a potential ligand by performing structure-based drug design with the three-dimensional structure determined for the crystal, wherein said selecting is performed in conjunction with computer modeling;

(b) contacting the potential ligand with the ligand binding domain of factor VIII;  
and

(c) detecting the binding of the potential ligand for the ligand binding domain; wherein a potential drug is selected on the basis of its having a greater affinity for the ligand binding domain of factor VIII than that of a standard ligand for the ligand binding domain of factor VIII.

12. (original) The method of claim 11, wherein the standard ligand is glycerophosphorylserine, phosphate or sulfate.

13. (original) A method of using N-terminal truncated factor VIII to grow a crystal of a protein-ligand complex, comprising:

(a) contacting the N-terminal truncated factor VIII with a ligand, wherein the N-terminal truncated factor VIII forms a protein-ligand complex with the ligand; and

(b) growing the crystal of the protein-ligand complex; wherein the crystal effectively diffracts X-rays for the determination of the atomic coordinates of the protein-ligand complex to a resolution of greater than 5.0 Angstroms.

14. (original) The method of claim 13, wherein said growing is performed by sitting-drop vapor diffusion.

15. (original) The method of claim 13, wherein said ligand is glycerophosphorylserine.